Lymphocyte proliferation during PUVA therapy

Area of Science:

• Immunology
• Dermatology
• Photochemotherapy

Background:

• Psoriasis involves immune dysregulation, with lymphocyte proliferation playing a key role.
• PUVA (psoralen plus UVA) therapy is a common treatment for psoriasis.
• The precise immunomodulatory effects of 8-methoxypsoralen (8-MOP) during PUVA therapy require further elucidation.

Purpose of the Study:

• To investigate the impact of 8-methoxypsoralen (8-MOP) on lymphocyte proliferation in psoriatic patients undergoing PUVA therapy.
• To determine if 8-MOP alone, or in combination with UVA irradiation, affects lymphocyte responsiveness to various mitogens and antigens.

Main Methods:

• Studied lymphocyte proliferation in 15 psoriatic patients.
• Stimulated lymphocytes with tuberculin, trichophytin, varidase, concanavalin A (Con A), and pokeweed mitogen (PWM).
• Assessed proliferation at various time points during the first and eighth PUVA treatments: after 8-MOP intake, immediately post-UVA, and 24 hours later.

Main Results:

• A significant decrease in lymphocyte proliferation was observed after 8-MOP intake during the first PUVA treatment when stimulated with Con A, trichophytin, and varidase.
• This suppressive effect of 8-MOP was not significantly altered by subsequent UVA irradiation or present after 24 hours.
• No 'dark effect' of 8-MOP on lymphocyte proliferation was detected during the eighth treatment, suggesting a modification in lymphocyte surface structure.

Conclusions:

• 8-methoxypsoralen (8-MOP) transiently inhibits lymphocyte proliferation in psoriatic patients during early PUVA therapy, potentially by interacting with the cell surface.
• The diminishing effect of 8-MOP during PUVA treatment may be attributed to adaptive changes in lymphocyte surface structures.
• These findings offer insights into the immunomodulatory mechanisms of PUVA therapy in psoriasis.